Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir

Peter A. C. Wing, Meleri Jones, Michelle Cheung, Sampath DaSilva, Connor Bamford, Wing-Yiu Jason Lee, Elihu Aranday-Cortes, Ana Da Silva Filipe, John McLauchlan, David Smith, William Irving, Morven Cunningham, Azim Ansari, Eleanor Barnes, and Graham R. Foster

BACKGROUND & AIMS: Sofosbuvir is a frequently used pan-genotype inhibitor of hepatitis C virus (HCV) polymerase. This drug eliminates most chronic HCV infections, and resistance-associated substitutions in the polymerase are rare. However, HCV genotype 3 responds slightly less well to sofosbuvir-based therapies than other genotypes. We collected data from England’s National Health Service Early Access Program to search for virus factors associated with sofosbuvir treatment failure. METHODS: We collected patient serum samples and used the capture-fusion assay to assess viral sensitivity to sofosbuvir in 14 HCV genotype 3 samples. We identified polymorphisms associated with reduced response and created modified forms of HCV and replicons containing the substitutions of interest and tested their sensitivity to sofosbuvir and ribavirin. We examined the effects of these polymorphisms by performing logistic regression multivariate analysis on their association with sustained virologic response in a separate cohort of 411 patients with chronic HCV genotype 3 infection who had been treated with sofosbuvir and ribavirin, with or without pegylated interferon. RESULTS: We identified a substitution in the HCV genotype 3a NS5b polymerase at amino acid 150 (alanine [A] to valine [V]), V at position 150 was observed in 42% of patients with a reduced response to sofosbuvir in virus replication assays. In patients treated with sofosbuvir-containing regimens, the A150V variant was associated with a reduced response to treatment with sofosbuvir and ribavirin, with or without pegylated interferon. In 326 patients with V at position 150, 71% achieved an sustained virologic response compared to 88% with A at position 150. In cells, V at position 150 reduced the response to sofosbuvir 7-fold. We found that another rare substitution, glutamic acid (E) at position 206, significantly reduced the response to sofosbuvir (8.34-fold reduction); the combinations of V at position 150 and E at position 206 reduced the virus response to sofosbuvir 35.77-fold. Additionally, in a single patient, we identified 5 rare polymorphisms that reduced sensitivity to sofosbuvir our cell system. CONCLUSIONS: A common polymorphism, V at position 150 and E at position 206 reduced the virus response to sofosbuvir 35.77-fold. Additionally, in a single patient, we identified 5 rare polymorphisms that reduced sensitivity to sofosbuvir our cell system. The recent introduction of triple-therapy regimens (SOF with a pan-genotypic protease and NS5a inhibitors) provides an alternative to the current approach to therapy, which combines SOF with an NS5a inhibitor alone. However, protease inhibitors are contraindicated in patients with decompensated cirrhosis, and in such patients, the only available therapy is SOF plus an NS5a inhibitor. It is not known which patients require triple therapy and it is not clear whether this regimen should be reserved as a retreatment option for the few patients who do not respond to dual therapy.

Abbreviations used in this paper: CI, confidence interval; DAC, daclatasvir; HCV, hepatitis C virus; IC50, 50% inhibitory concentration; IFN, interferon; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virologic response; Wt, wild-type.

© 2019 by the AGA Institute. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
In vitro, a variant at position 282 (S282T polymorphism) is polymorphic, rapidly evolving virus has, to date, not identified very few patients to examine. Viral sequencing of this highly sensitive to treatment. This discovery could increase our understanding of mechanisms of treatment failure and might change treatment regimens for patients with HCV genotype 3 infection.

**NEW FINDINGS**

The authors identified polymorphisms in genotype 3 HCV (A150V and K206E) that reduce the response to sofosbuvir. The A150V variant is common and K206E variant is rare. Additional very rare polymorphisms reduce the response in combination.

**LIMITATIONS**

Additional study is needed on the role of this polymorphism in disease progression and sensitivity to triple therapy.

**IMPACT**

The authors identified a polymorphism in HCV genotype 3 that affects virus response to treatment. This discovery could increase our understanding of mechanisms of treatment failure and might change treatment regimens for patients with HCV genotype 3 infection.

HCV genotype 3a is common in the Indian sub-continent and comprises 30% of all HCV infections in Eastern and Western Europe. Patients infected with this genotype respond well to IFN-based regimens, with response rates approaching 80% in patients without cirrhosis, although the response is greatly reduced in those with advanced fibrosis. SOF is active against HCV genotype 3 and in combination with the pan-genotypic NS5a inhibitor velpatasvir, >90% of patients respond. However, response rates with SOF/velpatasvir are lower in patients with cirrhosis than in those with lesser degrees of fibrosis and the response to therapy is further reduced in patients previously exposed to IFN-based therapies. For patients with decompensated cirrhosis, for which protease inhibitors are contraindicated, response rates for patients with genotype 3 may be as low as 50%. It is unclear why HCV genotype 3 is less sensitive to SOF than other HCV genotypes, and it is not known why prior therapy with IFN impacts response.

The extraordinary success of SOF-based treatments in both clinical trials and real-world studies, with sustained virologic response (SVR) rates of >95%, has reduced the opportunity to study patients who do not respond—there are very few patients to examine. Viral sequencing of this highly polymorphic, rapidly evolving virus has, to date, not identified motifs clearly associated with a reduced response to SOF. In vitro, a variant at position 282 (S282T polymorphism) is commonly selected, although it does have a reduced replication capacity. In clinical studies, the S282T variant is rarely seen and the “resistance polymorphisms” that have been reported after antiviral therapy (L159F and V321A) do not appear to reduce the effectiveness of SOF in viral replication models. Studies identifying treatment outcome of pre-existing resistance variants in baseline clinical samples show that presence of variants susceptible to treatment can dilute the effect of resistance variants to therapy. This suggests that polymorphisms that reduce response to SOF will be difficult to detect by sequence analysis alone. A more informative approach would be to combine high-throughput sequencing data with in vitro antiviral phenotyping of clinical isolates to identify rare motifs that impact viral response to SOF and other potent antiviral agents.

To address the issue of “SOF resistance,” we studied patients from the National Health Service England Early Access Programme, which offered antiviral therapy with SOF, RBV, and NS5a inhibitors (either daclatasvir [DAC] or ledipasvir) to patients with advanced liver disease. The program was initiated before drug licensing and used treatment durations for HCV genotype 3 infection that, in retrospect, may have been suboptimal, that is, 12 weeks, rather than the now recommended 24 weeks. The high relapse rate (approximately 30%) in patients with HCV genotype 3 prompted a search for viral factors associated with SOF treatment failure.

**Methods**

**Study Samples**

Serum and plasma samples from patients who donated samples to the HCV Research UK Biobank were used after informed consent and approval by the Biobank Tissue Access Committee, as approved by a UK Ethical Review Committee. Additional samples were obtained after informed consent and Ethics Committee approval from patients attending the Royal London Hospital.

**In Vitro Analysis**

Viral phenotyping was performed using the “capture-fusion” viral replication assay in which infected serum is incubated with monocytes before fusion of HCV containing monocytes with hepatocytes. Library preparation, sequencing, assembly, and variant detection are described in the Supplementary Methods.

**Site-Directed Mutagenesis and Transfection**

**Hepatitis C Virus Replicon Constructs**

Nucleotide changes were introduced into the genotype 3 S52-(SHI) sub-genomic replicon (a kind gift from Charlie Rice), and the full-length genotype 3 DBN (a kind gift from Jens Bulh) clone using the Quick-Change II XL site-directed mutagenesis kit (Agilent, Santa Clara, CA). Nucleotide changes were confirmed by Sanger sequencing (Cambridge Bioscience, Cambridge, UK). Replicon plasmids were linearized with XbaI, treated with mung bean nuclease, purified, and in vitro-transcribed using the MEGAscript T7 Transcription kit (Ambion, Austin, TX). For electroporation, cells were washed twice with ice-cold phosphate buffered saline and diluted to a concentration of 5 x 10⁶ cells/mL. Five micromolars of purified RNA was mixed with 400 µL cell suspension and electroporated using a BioRad GenePulser II on the exponential setting (pulse settings: 250V and 950 µF). To generate the stable replicon cells, cells were grown with G418 (750 µg/mL). For antiviral drug assays, cells were transferred to complete medium and seeded into 96-well plates and left to recover for 24 hours. Antiviral drugs were added for 72 hours, after which cells were lysed in 1X passive lysis buffer and firefly luciferase activity.
was measured as per manufacturer’s instructions (Promega, Madison, WI).

**Generation of Infectious Genotype 3 Derived Cell Culture Hepatitis C Virus**

Huh7.5-SEC14L2 cells were seeded in a 6-well plate at a density of $4.2 \times 10^5$ cells/well 24 hours before transfection. Lipofectamine 3000 (3.75 µL) was diluted in 125 µL of Opti-MEM and 5 µg of DBN3acc RNA was diluted in 250 µL of OptiMEM. Both mixes were incubated at room temperature for 5 minutes before combining, after which the reaction mixture was incubated for an additional 20 minutes at room temperature and then added drop wise to the cells. After 24 hours, cells were placed in Dulbecco’s modified Eagle medium 10% fetal calf serum and expanded into T25-cm² then T75-cm² flasks. At

**Figure 1.** SOF sensitivity in HCV genotype 3 treatment non-responders to direct-acting antiviral (DAA) therapy was assessed using the capture-fusion assay. Sera from patients with HCV genotype 3 (n = 14) who achieved SVR (blue) or relapsed (red) were used to assess sensitivity to SOF and RBV. Changes in HCV RNA for SOF and RBV in patients who achieved SVR (n = 4) (A, E) or relapsed are shown. Samples from patients who relapsed were further divided into 2 groups, depending on the assay outcome, those who were SOF- and RBV-sensitive (n = 4) (B, F) and insensitive (n = 6) (C, G). Data were summarized in (D; SOF) and (G; RBV) to show HCV RNA as a percentage of no drug treatment for a single dose of drug (0.25 µM of SOF and 0.75 µM of RBV). Graphs show mean ± SEM. $P$ values were calculated using Kruskal-Wallis test. Drug sensitivity of each sample was assessed in quadruplicate for each concentration.
Table 1. Identified Polymorphisms Within the NS5B of the Phenotypes Samples

| Patient no. | Therapy | Therapy outcome | Assay outcome (SOF) | Drug sensitivity | Relevant polymorphisms, % (pre→post therapy) |
|-------------|---------|----------------|--------------------|-----------------|---------------------------------------------|
|             |         |                | SOF IC$_{50}$, μM  | RBV IC$_{50}$, μM | K100R A150V A150S G188D K206E T213N N244I |
| 1           | SOF/DAC/RBV | SVR | Sensitive | 0.039 | 0.786 | — | V (98) | — | — | — | — | — | — |
| 2           | SOF/VEL   | SVR | Sensitive | 0.034 | 0.545 | — | — | — | — | — | — | — | — |
| 3           | SOF+OBV /PTV/RBV | SVR | Sensitive | 0.011 | 0.419 | — | — | — | — | — | — | — | — |
| 4           | SOF/DAC   | SVR | Sensitive | 0.054 | 0.19  | — | — | — | — | — | E (98) | — | — |
| 5           | SOF/LDV/RBV | Relapse | Sensitive | 0.06  | 0.43  | — | — | — | — | — | E (99) | — | — |
| 6           | SOF/DAC/RBV | Relapse | Sensitive | 0.033 | 0.886 | — | — | — | — | — | E (99) | — | — |
| 7           | SOF/LDV/RBV | Relapse | Sensitive | 0.04  | 0.72  | — | V (98) | — | — | — | — | — | — |
| 8           | SOF/LDV   | Relapse | Sensitive | 0.02  | 0.701 | — | — | — | — | — | — | — | — |
| 9           | SOF/DAC/RBV | Relapse | Insensitive | >0.25 | >1.25 | R (65→98) | — | S (98→99) | D (98→97) | — | N (98→99) | I (94→99) | — | — |
| 10          | SOF/LDV/RBV | Relapse | Insensitive | >0.25 | >1.25 | R (97→98) | V (54→98) | — | — | — | E (89→99) | — | — | — |
| 11          | SOF/LDV/RBV | Relapse | Insensitive | >0.25 | >1.25 | — | V (98→95) | — | — | — | E (89→99) | — | — | — |
| 12          | SOF/DAC/RBV | Relapse | Insensitive | >0.25 | >1.25 | — | V (98→97) | — | — | — | E (100→99) | — | — | — |
| 13          | SOF/LDV/RBV | Relapse | Insensitive | >0.25 | >1.25 | — | V (98→99) | — | — | — | E (98→99) | — | — | — |
| 14          | SOF/LDV/RBV | Relapse | Insensitive | >0.25 | >1.25 | — | V (99) | — | — | — | E (100)* | — | — | — |

NOTE. Patients were divided into 3 groups (SVR-sensitive, relapse-sensitive, and relapse-insensitive) based on therapy and assay outcomes. Samples were deemed to be SOF-insensitive if a single dose of the antiviral drug (0.25 μM) did not reduce the HCV RNA levels to <80% of the no-drug control in the capture fusion assay. Polymorphisms were identified by comparison of NS5b next-generation sequencing data from drug-sensitive vs drug-insensitive samples. The majority of the polymorphisms were identified in the assay-insensitive group, with a specific pattern (A150V and K206E) seen in patients 10–14. Percentage values indicate the frequency of each polymorphism present in the viral populations.

LDV, ledipasvir.

*No post-treatment sequencing data were obtained for sample 14 due to low viral load post relapse.
7 days post transfection, cells were seeded onto coverslips to assess presence of HCV replication complexes by NS5a immunofluorescence. Once >50% of cells were deemed to be positive for HCV, supernatants from the transfected cells were filter-sterilized using a 0.45-μm syringe filter, aliquoted, and stored at -80°C.

**Statistical Analysis**

Multivariate logistic regression was used for the analysis of association between SVR and the viral polymorphisms A150V and K206E and to test for interaction between the 2 sites and its impact on the SVR. To account for population structure of the host and the virus, we performed principal component analysis on host genome-wide genotype data and on virus whole genome nucleotide data. Two virus principal components and 3 host principal components were used as covariates in the model to account for the host and virus population structures. We also added patients’ IFNL4 genotypes (CC vs non-CC), cirrhosis status, and previous IFN-based treatment status in our model as covariates to account for possible confounding. The multiple comparisons in the capture fusion assay experiments were analyzed using Kruskal-Wallis analysis and changes in drug sensitivity in replication asssays were determined to be statistically significant if the 95% confidence intervals (CIs) did not overlap.

**Results**

**Viral Phenotyping Reveals Distinct Patterns of Polymorphisms in Patients With a Reduced Response to Sofosbuvir**

We used the capture-fusion assay\(^1\) to assess SOF and RBV sensitivity of 14 HCV genotype 3 samples. These included pretreatment viral samples sourced from patients with advanced liver disease from the National Health Service England Early Access Programme (n = 10) and 4 additional HCV genotype 3 samples from patients who had either responded to therapy in the early access program (n = 2) or had previously shown a response to SOF in vitro (n = 2) and were later treated successfully. Samples from SOF-treated patients were selected on the basis of viral load (>1 × 10\(^5\) IU/mL) and availability (Supplementary Table 1). Sensitivity of samples was assessed by treatment of infected cells with a range of SOF and RBV doses (0–0.25 μM and 0–1.25 μM, respectively) and measurement of HCV RNA in response to drug treatment (SOF, Figure 1A–D and RBV, Figure 1E–G). These analyses were performed without prior knowledge of treatment outcome. After unblinding, drug sensitivity data for all samples tested were grouped into treatment outcome. Samples from patients who achieved SVR demonstrated a significant reduction in HCV RNA in response to treatment with SOF (Figure 1A) and RBV (Figure 1E). Note that in the capture-fusion assay, residual signal leads to apparent detection of virus even at high doses of inhibitor and hence viral replication does not fall to zero. Data obtained from samples from patients who relapsed showed 3 distinct patterns of response to SOF. We defined these as “relapse sensitive” or “relapse insensitive,” based on an examination of the dose–response curves. Significant reductions in HCV RNA were only seen in 4 samples in response to SOF and RBV (Figure 1B and F, “sensitive” sample), while the majority of samples from patients who relapsed (n = 6) exhibited no substantial change in HCV RNA when treated with a range of SOF and RBV doses (“insensitive” samples). To highlight the different drug sensitivities between the sample groups, we analyzed the percentage change in HCV RNA compared to the no-drug control at individual doses of 0.25 μM SOF (Figure 1D) and 0.75 μM RBV (Figure 1F). A mid-range dose of RBV was selected for the comparison due to some cytoxicity at high RBV concentrations (see Supplementary Figure 1). Four viral samples from patients who relapsed showed a comparable reduction in HCV RNA to samples from patients who achieved SVR, while 6 of the 10 samples from patients who relapsed showed no change in HCV RNA with SOF or RBV treatment at this dose.

Samples were subjected to high-throughout, next-generation sequencing with substitutions present in <15% of the sequencing reads discarded. Viral sequences were then compared to the reference genotype 3a sequence (NC_004102) (Table 1). No reported SOF resistance associated substitutions (L159F, S282T, or V321A\(^2\)) were found, but 5 of 6 SOF “insensitive” samples had polymorphisms in domains 1 and 2 of the polymerase protein—A150V and K206E—that were not seen in combination in the sensitive samples, although the individual substitutions were observed. The other SOF-insensitive patient had 5 changes, 4 of which were unique (A150S, G188D, T213N, and N244I).

**Prevalence and Impact of NS5b Mutations in a Second Patient Cohort**

The reference sequences of the 7 HCV genotypes were aligned and the amino acids at the polymorphisms of interest were compared (Supplementary Figure 2A). Positions 150, 213, and 244 appeared to be the least conserved across the genotypes. Alignment of 1200 HCV genotype 3a sequences from the HCV-GLUE database (a UK-based database of published HCV sequences)\(^2\) (amino acids 91–250) (Supplementary Figure 2B) showed that amino acids 150 and 206 were the least conserved of the positions of interest and that amino acid 150, in particular, is highly polymorphic. In comparison, available sequences for HCV genotype 3b in HCV-GLUE shows that alanine at position 150 is dominant (n = 39/42). In HCV genotype 3a sequences, alanine at position 150 is present at a frequency of 40.65%, with the valine variant present at a frequency of 36.66%. The variation at position 206 is much less pronounced, with lysine (K) dominating at a frequency of 76.31% and glutamic acid (E) seen at a frequency of only 12.74%. An analysis of the combination of both polymorphisms, alanine at position 150 and glutamic acid at position 206 (A150V_K206E), was present in <4% of the population, making this a rare combination.

We examined the impact of the polymorphisms of interest in pretreatment samples from a cohort of HCV
Figure 2. 3-Dimensional model of the HCV polymerase NS5b (A, front; B, back; C, top) derived from the JFH-1 crystal structure with the location of the polymorphisms of interest shown in purple. The structure in the center represents a bound RNA strand. PDB crystal structure ID: 4WTG. Structure was annotated using the Chimera software. dNTP, deoxyribonucleotide triphosphate; dsRNA, double-stranded RNA.
genotype 3 patients who were treated using SOF and RBV, with or without pegylated IFN (BOSON trial). In this cohort, the frequency of the polymorphisms seen in patient 9 (above) were too low to provide meaningful data (individually all were present in <10% of the population and combinations were present in fewer than 10 patients), but A150V and K206E polymorphisms were common (Supplementary Figure 2C). We investigated the association between A150V and K206E amino acid substitutions and outcome (Supplementary Figure 2D). To limit the impact of population structure and host genetics, we investigated patients with self-reported white ancestry and genotype 3a virus (n = 411 patients). At site 150 in NS5b protein, the most commonly observed amino acids were valine (42% = 170/407) and alanine (38% = 156/407). We also observed threonine (n = 13%), isoleucine (4%), serine (1.5%), glycine (1%), and asparagine (0.5%). As valine was the most common variant identified in our phenotypic studies, we analyzed isolates carrying valine or alanine at this site (n = 326). In logistic regression multivariate analysis accounting for population structure of virus and host (using principal component analysis), host IFNL4 genotype (CC vs non-CC), cirrhosis status, and previous treatment status, the polymorphism A150V was associated with an increase in relapse (P = .0027; SVR in patients whose virus carries alanine at position 150 = 88% [n = 138/156] and valine at position 150 = 71% [n = 121/170]) (Supplementary Figure 1C).

At site 206 in NS5b, the most commonly observed amino acids were lysine at 79% (n = 323/410) and glutamic acid at 13% (n = 54/410). We also observed glutamine (5%), threonine (2.4%), and, rarely, asparagine and aspartic acid.

Figure 3. Huh7.5-SEC14L2 cells transiently transfected (by electroporation) with luciferase-containing HCV (S52-replicon) constructs with the NS5b polymorphisms from patient 9 (see Table 1). Cells were treated with SOF for 72 hours and replication was determined by luciferase assay, normalized to a sample 4 hours post electroporation for each construct. As a control for SOF non-response, a replicon containing the S282T NS5b mutation was included. Panels A–E indicate the effect of the polymorphisms from patient 9 to SOF sensitivity. IC50 values with 95% CIs were calculated by determining the drug concentration that affected a 50% reduction in HCV RNA and are summarized in Table 2. Mean values per drug concentration are plotted ± SEM. The above is representative of at least 3 independent experiments.
We used the same logistic regression model and included isolates carrying lysine or glutamic acid for analysis \( n = 377 \). We did not observe an association between the polymorphism K206E and treatment outcome \( (P = .26; \text{SVR in patients whose virus carries } K206 = 79\% [n = 255/323] \text{ and } E206 = 83\% [n = 45/54]) \).

To look at the interactions among the 3 sites, we included isolates carrying A or V at site 150 and K or E at site 206 in NS5b protein \( (AE = 25, AK = 120, VE = 16, \text{ and } VK = 139) \). Using the same multivariate logistic regression, including an interaction term between the 2 polymorphisms A150V and K206E, we observed no significant interaction.

![Figure 4](image-url)

**Figure 4.** Huh7.5-SEC14L2 cells were transiently transfected (by electroporation) with luciferase containing HCV (S52-replicon) with Wt, 150V, and 206E, individually and in combination. Cells were treated with SOF for 72 hours and HCV replication was measured using a luciferase assay and normalized to a sample 4 hours post electroporation for each construct. **Panels A–C** indicate the effect of the polymorphisms (A150V and K206E) from patients 10–14 on SOF sensitivity. IC\(_{50}\) values with 95% CIs were calculated by determining the drug concentration that affected a 50% reduction in replication. Mean values per drug concentration are plotted \( \pm \text{SEM}. \) The above is representative of at least 3 independent experiments.
between the 2 substitutions \((P = .13)\). Analyzing the haplotypes, we observed the lowest rate of SVR in patients whose virus carries the VK haplotype at 68% \((n = 95/139)\), while the other haplotype carriers all had higher rates of SVR \((AK = 89\% \ [n = 107/120]\), AE = 88\% \ [n = 22/25]\), and VE = 81\% \ [n = 13/16]\).

**Structural Relevance of the Identified Polymorphisms in Hepatitis C Virus NS5b**

To examine the structural significance of the observed polymorphisms, we plotted their location on a structural model of the HCV NS5b RNA polymerase. The crystal structure of the HCV genotype 3 NS5b has not been determined and we therefore used the well-established structure for strain JFH-1, a genotype 2a isolate.\(^2\) Most substitutions were located within domains I ("fingers") and II ("palm") of the protein \((Figure 2)\). The palm domain contains the catalytic triad that forms the enzymatic active site. Highly conserved residues, crucial for the active site, are located at positions D220, D225, G317, D318, and D319.\(^{24,25}\) While none of our identified positions are part of or adjacent to residues of the active site, 2 positions are in close proximity, K206E and T213N. The structural model shows that K206 (LYS-206) forms part of an α-helix close to the RNA binding cleft, but not directly within it. This residue is also close to a domain previously reported crucial for the RNA binding capacity of NS5b.\(^{26}\) Thr-213, however, is more distant from the catalytic site of the polymerase in the model.

The catalytic activity of NS5b is modulated by a direct interaction with NS5a.\(^{27,28}\) This stimulates activity of the polymerase but can also inhibit activity in a dose-dependent manner.\(^{29}\) Specific domains on the NS5b are crucial for this interaction and include residues 143–145, 149–155, 365–371, and 382–388. A150V is located within one of these domains, which may affect NS5a binding and thereby potentially modulate the catalytic activity of NS5b. From a structural context, position 150 in NS5b is found within the finger domain—between the lysine-rich ends of the finger on a flexible loop that protrudes from the surface. This motif is highly conserved at its N- and C-termini, where a number of amino acids with positively charged side chains interact with incoming nucleotide triphosphates transiting to the active site and nucleotide binding pocket. This region is highly variable in sequence and likely structure. In the crystal structure of the closed conformation of the JFH-1 strain NS5b, residue 150 is on the end of a loop, protruding from the molecule over the nucleotide entry tunnel. Note that JFH-1 NS5b has a similar sequence in the finger-loop domain to genotype 3a. This loop is likely to be dynamic and not highly structured, as observed in flaviviruses and human immunodeficiency virus, where nucleotide interactions can trigger conformational changes in the finger domain, bringing it closer to the body of the polymerase toward the active site.\(^{30}\)

**Effect of NS5b Polymorphisms on Drug Sensitivity**

We examined the impact of the polymorphisms in modified HCV genotype 3 sub-genomic replicons. The identified polymorphisms were introduced into the SS2 genotype 3 replicon\(^3\) and the nucleotide changes were confirmed by Sanger sequencing. The unique pattern of polymorphisms seen in patient 9 were associated with changes in sensitivity to SOF \((Figure 3A–E and Table 2)\) and RBV \((Supplementary Figure 3A–E and Supplementary Table 2)\). The largest impact on SOF sensitivity by an individual polymorphism was seen with N244I \((a 16\,-\text{fold} \text{ increase in } IC_{50}\text{ with non-overlapping CI})\). The K100R and T213N polymorphisms had a minimal impact on SOF sensitivity. The G188D polymorphism had a more marked effect \((10\,-\text{fold} \text{ increase in } IC_{50}\text{ with non-overlapping CI})\), but in combination with the K100R polymorphism, the effect on SOF sensitivity was increased and comparable to the level seen with the S282T variant. It should be noted that the combination of K100R and G188D and the N244I replicons had the greatest reduction in replication efficiency, as measured by relative luciferase (RLU) levels in comparison to the wild type \((Wt)\). Attempts to generate viable replicons with further combinations of polymorphisms were not successful, precluding a full analysis of all of the variants and their interactions, but it is clear that combinations of mutations in HCV NS5b can modify the SOF response. Some of these polymorphisms \((noticeably K100R)\) also reduced the effects of RBV. Given that patient 9 also had the Y93H NS5a polymorphism \((Supplementary Table 1)\), known to modify the response to NS5a inhibitors, we speculate that multiple polymorphisms are required to influence the clinical response to short courses of SOF-based therapies. Intriguingly, patient 9 cleared the virus with a prolonged course of SOF/DAC and RBV therapy.

**Analysis of the A150V and K206E Polymorphisms**

Examination of the common A150V and K206E polymorphisms in a transient replicon assay \((Figure 4 and Table 2)\) individually showed a reduced sensitivity to SOF \((8\,-\text{fold})\) with non-overlapping CI. The combined polymorphisms \((A150V and K206E)\) further reduced sensitivity to SOF \((>35\,-\text{fold})\) with non-overlapping CI. The effect of these polymorphisms on RBV sensitivity ranged from 10-fold for K206E to >40-fold change in IC\(_{50}\) for A150V, but in combination, the effect was enhanced \(\text{(approximately 70-fold change in IC}_{50}\text{ with non-overlapping CI). (Supplementary Figure 4 and Supplementary Table 2).}\)

The transient subgenomic replicon assays demonstrated that NS5b polymorphisms A150V and K206E impact the sensitivity of the polymerase to both SOF and RBV. We sought to confirm our findings in an infectious HCV model, which covers all stages of the viral lifecycle and may be more representative of the situation in vivo. The A150V and K206E polymorphisms were engineered individually and in combination into the DBN3acc virus,\(^3\) and the presence of the substitution was confirmed by Sanger sequencing. Cells were transfected to generate virus stocks, and the presence of the DBN3acc was confirmed by immunofluorescence for NS5a \((Supplementary Figure 5)\). The viral stocks generated were analyzed by NGS up to 26 days in culture and no nucleotide changes or new cell culture adaptations were observed \(\text{(data not shown).}\)
viral kinetics of the Wt virus and the polymorphisms A150V, K206E, and their combination were assessed over a 72-hour period. Up to 48 hours, the presence of polymorphisms did not have a significant impact on the infectivity, however, by 72 hours, a reduction in HCV RNA was observed in all viruses with the polymorphisms compared to the Wt (Supplementary Figure 6A). To further assess whether either the A150V or K206E polymorphism altered the viral fitness, the individual viruses were mixed with Wt virus at an equal ratio based on infectivity titer and used to infect naive cells.32 Next-generation sequencing analysis of the infected cells over 72 hours demonstrated that the introduced polymorphisms did not confer a fitness advantage to the viruses, no virus dominated at any time point (Supplementary Figure 6B–C), suggesting that the observed changes in drug sensitivity were not due to enhanced viral replication.

Next, we tested the sensitivity of our modified viruses to SOF, RBV, and DAC. We found that these viruses demonstrated a higher sensitivity to SOF than sub-genomic replicons yet the A150V and K206E mutations independently and in combination reduced the sensitivity to SOF (Figure 5A), confirming our previous findings. Additional reductions in sensitivity to RBV were also observed.
(Figure 5B), though these changes where not as pronounced as in previous replicon assays. Viruses were also assessed for their response to the NS5a inhibitor DAC (Figure 5C), no difference in sensitivity to either polymorphism, expressed individually or in combination in comparison to the Wt was observed. Together these data indicate that the polymorphisms A150V and K206E in the HCV NS5b polymerase individually and in combination cause a significant alteration in sensitivity to SOF in both replicon and infectious models.

Discussion

SOF is a central component of some of the most effective drug regimens for the treatment of hepatitis C and a full understanding of its strengths and weaknesses will be important to ensuring it continues to be deployed appropriately. This is of particular importance, given the availability of alternative regimens for HCV genotype 3 that are based on the protease inhibitor glecaprevir. Studies on SOF “resistance” have been hampered by the extraordinary efficacy of the drug, which has led to very few treatment failures, although some very rare polymorphisms that can modify response, particularly in genotype 1 infection, have been identified. Viral resistance is normally identified by post-treatment emergence of variants that can be shown to reduce drug efficacy in laboratory studies. However, the marked variability of hepatitis C with multiple, rapidly evolving polymorphisms makes identification of “resistance-associated substitutions” difficult and very large cohorts are required. This is illustrated by the initial trial examining 8 weeks of SOF plus ledipasvir for 8 weeks, which did not suggest any impact of resistance-associated variants in the NS5a protein, but subsequent analysis of more than 2000 patients from multiple studies showed that variants in the NS5a protein modify response. It is thus very difficult to evaluate the mechanisms underlying a failure to respond to SOF-based regimens with classical approaches and with the increasing efficacy of combining SOF with a protease inhibitor and a NS5a inhibitor it is likely that identifying motifs associated with failure will require massive patient cohorts. It is believed that SOF does not generate significant viral resistance and can therefore be used successfully for retreatment regimens. This hypothesis has been confirmed by clinical studies in which patients who failed to respond to SOF were successfully retreated with a combination of SOF, velpatasvir, and voxilaprevir, although a tiny number of patients did not achieve a virologic response, and this was most marked in patients with genotype 3 HCV and cirrhosis who had failed to respond to an NS5a-containing regimen, where response was 93%. Given the difficulties of identifying SOF “resistance” by conventional sequence-based assays, we have adopted a phenotyping approach that has allowed us to examine previously unexplored viral variants that impact on the response to SOF.

SOF is a potent pan-genotypic antiviral drug, but patients infected with genotype 3 HCV respond less well than other genotypes, and response to therapy is further reduced by the presence of cirrhosis or previous failure to respond to IFN. We studied patients who failed to respond to SOF-containing regimens that are now known to be inadequate. Our analysis shows that reduced response to SOF may occur if multiple viral polymorphisms are combined.

The strength of this study is the use of multiple different phenotypic analyses on viral variants of interest coupled with a genetic analysis in a cohort of patients who received SOF-only therapies without potent NS5a inhibitors. The use of different assay systems (capture-fusion replication, viral replicons, and modified viruses) showed that different assays have different characteristics and the efficacy of SOF in vitro is heavily dependent on the assay deployed.

We do note that specific IC50 values for antiviral drugs tested in our assay against the recently characterized DBN3acc virus differ from those published previously. We attribute this difference to our use of RNA copies to measure viral response as opposed to quantifying cells positive for viral proteins. We found some reduction in replication efficiency in the modified replicons, however, the maximum changes were of a similar magnitude to those seen with the S282T variant, and we therefore do not believe that they significantly alter our conclusions that these mutations impair the efficacy of SOF. Previous studies suggest that an increase in replicative fitness can modify antiviral sensitivity, but as the modified viruses we generated in this study demonstrated no significant increase in replicative fitness, we can exclude this as an explanation for the observed changes in drug sensitivity.

Collectively, our observations may help to explain why SOF polymorphisms that emerge during therapy do not appear to affect the sensitivity to SOF in vitro. Indeed, recent studies that modeled SOF resistance in vitro identified variants that had a significant impact on viral sensitivity to SOF, but were rarely found in clinical isolates. It is unclear which of the different assays most accurately reflects the conditions in patients, but in this study we found a very consistent pattern of response—in all of the assays, the same polymorphisms had similar effects, although the magnitude differed quite markedly in the different assays. The main weakness of this study is the use of samples from treatment regimens that have been superseded by more potent drug combinations. However, treatment failure with the new, triple-therapy regimens is rare, and an analysis of the outcomes of such treatments will require very large, real-world cohorts that are only now beginning to emerge.

Clinically, our data show that unusual viral polymorphisms can impair the response to SOF. For treatment-naive patients, responses to SOF-based treatments are so effective that any impact of these viral variants is likely to be minimal, and we would not recommend that such patients undergo pretreatment “resistance” testing. For patients who have been exposed to multiple drug regimens (including IFN and NS5a inhibitors, which can lead to resistance-associated polymorphisms), we speculate that the polymorphisms identified here might be of significance, and we suggest that
pretreatment viral sequencing may be useful in selecting the optimal regimen for such patients. Further studies in large cohorts of patients exposed to diverse treatment regimens will no doubt identify the small cohorts of patients who require sophisticated virologic analysis before therapy.

Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org, and at https://doi.org/10.1053/j.gastro.2019.05.007.

References

1. Rodriguez-Torres M. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. Expert Rev Anti Infect Ther 2013;11:1269–1279.
2. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34–44.
3. Afadh N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889–1898.
4. Buti M, Callea JL, Lens S, et al. Simeprevir in combination with sofosbuvir in treatment-naive and -experienced patients with hepatitis C virus genotype 4 infection: a phase III, open-label, single-arm study (PLUTO). Aliment Pharmacol Ther 2017;45:468–475.
5. Donaldson EF, Harrington PR, O’Rear JJ, et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 2015;61:56–65.
6. Gane EJ, Shiffman ML, Etkorn K, et al. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in HCV patients previously treated with a direct-acting antiviral regimen. Hepatology 2017.
7. Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic hcv infection: 2 phase 3 randomized trials. Gastroenterology 2017;153:113–122.
8. Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 2017;376:2134–2146.
9. Foster GR, Afadh N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608–2617.
10. Petruzzello A, Marigliano S, Loquercio G, et al. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 2016;22:7824–7840.
11. D’Souza R, Glynn MJ, Ushiro-Lumb I, et al. Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. Clin Gastroenterol Hepatol 2005;3:910–917.
12. Shoeb D, Rowe IA, Freshwater D, et al. Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse. Eur J Gastroenterol Hepatol 2011;23:747–753.
13. Xu S, Doehle B, Rajaguru S, et al. In vitro selection of resistance to sofosbuvir in HCV replicons of genotype 1 to 6. Antivir Ther 2017;22:587–597.
14. Fourati S, Rodriguez C, Hezode C, et al. Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r. Hepatology 2019;69:513–523.
15. Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1–6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 2014;59:1666–1674.
16. Zeuzem S, Mizokami M, Pianko S, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol 2017;66:910–918.
17. Cheung MC, Walker AJ, Hudson BE, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741–747.
18. Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;64:1224–1231.
19. Cunningham ME, Javada A, Waters J, et al. Development and validation of a "capture-fusion" model to study drug sensitivity of patient-derived hepatitis C. Hepatology 2015;61:1192–1204.
20. Lontok E, Harrington P, Howe A, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology 2015;62:1623–1632.
21. Singer JB, McLauchlan J, Hughes J, Gifford RJ. GLUE: a flexible software system for virus sequence data. BMC Bioinformatics 2018;19:532.
22. Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015;149:1462–1470.
23. Appleby TC, Perry JK, Murakami E, et al. Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase. Science 2015;347:771–775.
24. Hagedorn CH. Hepatitis C Virus RNA-dependent RNA polymerase (NS5B Polymerase). Methods Mol Med 1999;19:365–372.
25. Waheed Y, Saeed U, Anjum S, et al. Development of global consensus sequence and analysis of highly conserved domains of the HCV NS5B protein. Hepat Med 2012;12(9):e6142.
26. Qin W, Yamashita T, Shirota Y, et al. Mutational analysis of the structure and functions of hepatitis C virus RNA-dependent RNA polymerase. Hepatology 2001;33:728–737.
27. Shirota Y, Luo H, Qin W, et al. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA
polymerase activity. J Biol Chem 2002;277:11149–11155.
28. Shimakami T, Hijioka M, Luo H, et al. Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon. J Virol 2004;78:2738–2748.
29. te Velthuis AJ. Common and unique features of viral RNA-dependent polymerases. Cell Mol Life Sci 2014;71:4403–4420.
30. Saeed M, Scheel TKH, Gottwein JM, et al. Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob Agents Chemother 2012;56:5365–5373.
31. Ramirez S, Mikkelsen LS, Gottwein JM, et al. Robust HCV genotype 3a infectious cell culture system permits identification of escape variants with resistance to sofosbuvir. Gastroenterology 2016;151:973–985 e2.
32. Sheldon J, Beach NM, Moreno E, et al. Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. J Virol 2014;88:12098–12111.
33. Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in hcv genotype 1 or 3 infection. N Engl J Med 2018;378:354–369.
34. Svarovskaia ES, Gane E, Dvory-Sobol H, et al. L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. J Infect Dis 2016;213:1240–1247.
35. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879–1888.
36. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Prevalence of resistance-associated substitutions in HCV NSSA, NSSB, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology 2016;151:501–512 e1.

Author names in bold designate shared co-first authorship.

Received June 6, 2018. Accepted May 7, 2019.

Reprint requests
Address requests for reprints to: Graham R, Foster, PhD, Barts Liver Centre, Blizzard Institute, 4 Newark Street, London E1 2AT, UK. e-mail: g.r.foster@qmul.ac.uk.

Acknowledgments
The authors acknowledge HCV Research UK for the clinical data and samples used for the study. The authors are grateful to Diana Brainard and John McHutchison (Gilead) for generously making samples from the BOSON trial available for academic studies.

Author contributions: PACW, MJ, MC, SD, W-YJL, and MC designed and completed the experimental work. WI provided samples and insights from the HCV Research UK Biobank. ADSF, EA-C, CB, and JM completed the sequencing work and analysis and contributed to the development of experiments. AA, EB, and DS analysed the association of the polymorphisms. GRF designed, secured funding for, designed the experiments, and supervised the work. All authors contributed to experimental design and analysis of the data and all authors contributed to the final manuscript. Peter A. C. Wing and Meleri Jones contributed equally to this work.

Conflicts of interest
These authors disclose the following: GRF has received speaker and consultancy fees from AbbVie, Gilead, and Merck. WI has received speaker and consultancy fees from Roche, Janssen Cilag, Gilead Sciences, and Novartis, educational grants from Boehringer Ingelheim, Merck Sharp and Dohme, and Gilead Sciences, and research grant support from GlaxoSmithKline, Pfizer, Gilead Sciences, Janssen Cilag, AbbVie, and Bristol-Myers Squibb. JM has received speaker and consultancy fees from AbbVie, Gilead Sciences, and Bristol-Myers Squibb. EB has received consultancy fees from Merck Sharp and Dohme, and research grants from AbbVie, Vaccitech, and GlaxoSmithKline. The remaining authors disclose no conflicts.

Funding
HCV Research UK was supported by the Medical Research Foundation (award number C0365). JM, CB, E-AC, and ADSF were supported by the UK Medical Research Council (MC_UU_12014/1) (MC_UU_12014/1). PW was funded by HCV Research UK through the Medical Research Foundation (award number C0365). EB is funded by the Medical Research Council UK, the Oxford National Institute for Health Research (NIHR) Biomedical Research Centre and is an NIHR Senior Investigator. The views expressed in this article are those of the author and not necessarily those of the National Health Service, NIHR, or Department of Health. We also acknowledge the Medical Research Council-funded STOP-HCV Consortium, who supported AA and the sequencing analysis in the BOSON study.
Supplementary Methods

Cells and Viral Phenotyping
Huh7.5-SEC14L2 cells (kind gift from P. Simmonds, Oxford, UK) were propagated in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum. ThP1 cells were propagated in RPMI supplemented with 10% fetal calf serum. Cytokines used for ThP-1 stimulation were phorbol 12-myristate 13-acetate (Sigma-Aldrich, Dorset, UK) and interferon gamma (Invitrogen, Paisley, UK). SOF was kindly provided by Gilead Sciences (Foster City CA), DAC by Bristol-Myers Squibb (New York, NY), and RBV by Sigma Aldrich (St Louis, MO). All antiviral drugs were reconstituted in dimethyl sulfoxide.

Viral phenotyping was performed using the capture-fusion viral replication assay, as described previously. Briefly, THP-1 cells were seeded into 6-well plates (10⁶ cells/mL) and maintained for 18 hours, with or without the addition of IFN gamma (10 ng/mL) and phorbol 12-myristate 13-acetate (200 ng/mL). Cells were washed 3 times and the medium replaced with RPMI/2% fetal calf serum and patient serum (1 HCV IU/cell). After incubation at 37°C for 18–24 hours, the supernatant was removed and cells were washed. Adherent cells were removed using a cell scraper and Huh7.5 cells added at a 1:1 ratio. Cell fusion was performed as above. The fused cells were seeded into 6-well plates at a density of 10⁵ cells/mL and maintained at 37°C in the presence or absence of antiviral drugs for 3 days.

HCV RNA was quantified by reverse-transcription polymerase chain reaction (PCR). Total RNA was extracted with TRIzol (Invitrogen) and quantified using RiboGreen (Invitrogen), according to the manufacturer’s instructions. One-step reverse transcription PCR (QuantiTect Virus Kit Qiagen, Crawley, UK) and TaqMan Gene Expression Assay HCV primer and probe (Applied Biosystems, Paisley, UK) were used for quantification. PCRs were performed in triplicate. Absolute quantification of HCV RNA was performed by including serial dilutions of an RNA standard in each PCR run and expressed relative to total sample RNA.

To assess cytotoxicity of antiviral drugs, cells were seeded in a 96-well plate in triplicate and incubated in the presence of a serial dilution of drugs for 72 hours. A 10X AlamarBlue reagent was added directly to the cell media and incubated for 3 hours at 37°C. Fluorescence at excitation wavelength of 560 nm and emission wavelength of 590 nm was then quantified.

Sequencing
Sequencing of patient samples by Metagenomic and Target Enrichment was performed after RNA extraction from 200 µl plasma (Agencourt RNAAdvance Blood kit; Beckman Coulter, Brea, CA), eluted into 11 µL water, and reverse transcribed (SuperScript III; Invitrogen) with random hexamers and a Second Strand Synthesis kit (New England Biolabs, Ipswich, MA). Library preparation was performed with the KAPA Library Prep kit (KAPA Biosystems, Wilmington, MA) with index tagging by 16 cycles of PCR using KAPA HiFi HotStart (KAPA Biosystems) and custom-synthesized multiplex oligos. Libraries were quantified by Qubit (ThermoFisher, Waltham, MA) and TapeStation (Agilent), pooled at equimolar concentrations for sequencing on the Illumina MiSeq (v3 chemistry; Illumina, San Diego, CA). For target enrichment, pooled libraries were enriched by the NimbleGen SeqCap EZ System (Roche, Basel, Switzerland), followed by sequencing on the Illumina MiSeq platform using v3 chemistry. Variant analysis was performed after Fastq file quality assessment using FastQC and Sam files were created by mapping against whole-genome HCV reference sequences. Assemblies were viewed using UGene and positions of interest identified in the GenBank HCV strain H77 polyprotein gene (accession no. AF011751). Each reference was aligned against HCV strain H77 to standardize the positions of interest and total base counts were identified at the variant positions.

Hepatitis C Virus Target Enrichment
RNA was isolated from 200 µL of cell culture supernatant using the RNAAdvance Blood extraction kit (Beckman Coulter) and collected in 27 µL water. After conversion of RNA to double-stranded DNA, libraries were prepared for Illumina sequencing using the KAPA DNA LTP Library Preparation Kit (Roche), and NEBNext Multiplex Oligos for Illumina (New England Biolabs). Libraries were quantified using Qubit dsDNA HS Assay Kit (Invitrogen) and size distribution assessed using Agilent TapeStation with D1K High Sensitivity Kit (Agilent); libraries were normalized according to viral load and mass. A 500-ng aliquot of the pooled library was enriched using SeqCap EZ Developer Probes (Roche) following manufacturer’s protocol. After a 14-cycle post-enrichment PCR, the cleaned pool was sequenced with 151 base-paired end reads on an Illumina NextSeq cartridge, with resulting reads characterized by Q30 >87%.

Site-Directed Mutation Primers
Outer NS5b primers encoding XhoI and XbaI restriction sites at the 5’ and 3’ end of NS5b

| Primer ID | Primer Sequence |
|-----------|-----------------|
| S52-5b    | GTGGCCGGGGCCGAGCTGGAGGGAGGGAC |
| S52-5b    | GTTGGCCGGGGCCGAGCTGGAGGGAGGGAC |
| S52-5b    | GTTGGCCGGGGCCGAGCTGGAGGGAGGGAC |
| S52-5b    | GTTGGCCGGGGCCGAGCTGGAGGGAGGGAC |

Overlapping primers designed to introduce the specified amino acid change in NS5b

| Primer ID | Primer Sequence |
|-----------|-----------------|
| S52-5b-K100R | CTGGCCGCAACCTCGACGGGACAGAAGAGGGAC |
| S52-5b-K100R | CTGGCCGCAACCTCGACGGGACAGAAGAGGGAC |
| S52-5b-K100R | CTGGCCGCAACCTCGACGGGACAGAAGAGGGAC |

HCV G3 Response to Sofosbuvir 704.e1
SS52-5b-K206E-R CTGGAGGTTCCACATCTCCAGTAGACGT
CTTGGGGTT
SS52-5b-T213N-F GAAGATGTGGACCTCAAAGAAAAACCC
CTTGGGGTT
SS52-5b-T213N-R AACCCCAAGGGGTTTTTCTTTGAGG
TCCACATCTTC
SS52-5b-N244I-F GGAAGATATATCAATGCTGTATCCTTGAA
ACCGGAGGC
SS52-5Bb-N244I-R GCCTCCGGTTCAAGGATACAGCA
TTGATATATCTCC.

Immunofluorescence

Cells were plated onto glass cover slips at $1 \times 10^4$/cm$^2$ 12–14 hours before experiment. Cells were then washed with phosphate buffered saline and fixed in ice-cold methanol at –20°C for 20 minutes and then washed in phosphate buffered saline and blocked with 3% fetal bovine serum for 1 hour at room temperature. The sheep polyclonal anti-NS5a (kind gift from Mark Harris, Leeds University) was diluted in blocking buffer at 1:1000 and cells were incubated for 1 hour at room temperature. Unbound primary antibody was removed by 3 washes with 1X phosphate buffered saline before incubation with Alexa Flour 488 donkey anti-sheep secondary antibody diluted to 1:1000 for 1 hour at room temperature. Cells were then incubated with 4′,6-diamidino-2-phenylindole (1:1000) for nucleus visualization.

Relative Fitness Assay

Growth-competitions experiments were established between the DBN_WT and DBN_A150V or DBN_K206E in Huh7.5 cells. Huh7.5 cells ($4 \times 10^5$) were infected with a 1:1 mixture of the 2 competing viruses, based on their infectivity titers (total, $1.2 \times 10^4$ median tissue culture infectious dose: multiplicity of infection of 0.03 median tissue culture infectious dose/cell), following Sheldon et al.$^2$ RNA was extracted from the initial mixture (0 hours) and from cells at 24, 48, and 72 hours post infection. PCR products were generated for the regions of interest with the addition of common sequence tags CS1 and CS2 to allow for the addition of a sample index barcode.

A150V-F
GACCCCAACCCCAATTCAACTACATAATGGA,
A150V-R
CACGTCATAGGCTGTTTCTCAGACAGCAGCACCCC,
K206E-F
GTCTGCCTACGGATTCCAATACTCGCCTCAACAGCG,
K206E-R
CTGTTCCGTGACAGTCGAGTCACAGCACCGGCTGTAC

Fastq files were decompressed and the grep command line tool used to perform a count analysis on each sample to determine the number of counts for each variant. A flanking region was used upstream and downstream of the variant site to ensure high sequence similarity. The following sequences were used:

A150V-alanine: GACCCCGCT
A150V-valine: GACCCCGTT
K206E-lysine: CTGCTGAAG
K206E-glutamic-acid: CTGCTGGAG

Counts for each sample were tabulated and a percentage of the total number of reads calculated. Any sample with <15 reads in total was considered a fail and these data were not reported.

References

1. Cunningham ME, Javaid A, Waters J, et al. Development and validation of a "capture-fusion" model to study drug sensitivity of patient-derived hepatitis C. Hepatology 2015;61:1192–1204.

2. Sheldon J, Beach NM, Moreno E, et al. Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. J Virol 2014;88:12098–12111.
Supplementary Figure 1. Huh7.5 cells were incubated with a serial dilution of RBV for 72 hours in triplicate. AlamarBlue reagent was added for 3 hours and fluorescence intensity was assessed as a measure of cytotoxicity.
A

| HCV genotype (NCBI Reference Sequence) | 100 | 150 | 188 | 206 | 213 | 244 |
|----------------------------------------|-----|-----|-----|-----|-----|-----|
| 1 (NC_004102)                          | K   | E   | G   | Q   | T   | D   |
| 2 (D00944)                             | K   | T   | G   | K   | D   | S   |
| 3 (NC_009824)                          | K   | A   | G   | K   | T   | N   |
| 4 (NC_009825)                          | K   | A   | G   | T   | D   | D   |
| 5 (NC_009826)                          | K   | S   | G   | K   | I   | D   |
| 6 (NC_009827)                          | R   | S   | G   | K   | T   | Q   |
| 7 (NC_030791)                          | K   | A   | G   | K   | T   | N   |

Supplementary Figure 2. (A) HCV genotype 1–7 amino acid sequences were aligned and the table shows the amino acid at the positions of interest and compared to the gt3a reference sequence. (B) Alignment of 1200 HCV genotype 3a sequences from the HCV-GLUE database identifying the minor variants at each position of interest. Legend designates the color code for each amino acid. (C) Analysis of the NS5b polymorphisms in the BOSON cohort, the prevalence of the NS5b polymorphisms was assessed from >500 viral sequencing samples obtained from the BOSON cohort. (D) Each mutation was tested to assess whether the frequency was significantly different between SVR and non-SVR samples. Frequencies were analyzed using Fisher’s exact test.
Supplementary Figure 3. Huh7.5-SEC cells transiently transfected (by electroporation) with luciferase containing HCV (S52-replicon) constructs with the indicated NS5b polymorphisms were assessed. Cells were treated with RBV for 72 hours and replication was measured using a luciferase assay, normalized to a sample 4 hours post electroporation for each construct. Panels A–E indicate the effect of the polymorphisms from patient 9 to RBV sensitivity. The above is representative of at least 3 independent experiments. Relative luciferase units (RLU).
Supplementary Figure 4. Huh7.5-SEC cells transiently transfected (by electroporation) with luciferase containing HCV (S52-replicon) constructs with the indicated NS5b polymorphisms were assessed. Cells were treated with RBV for 72 hours and replication was measured in a luciferase assay, normalized to a sample 4 hours post electroporation for each construct. Panels A–C indicate the effect of the polymorphisms from patients 10–14 on RBV sensitivity. The above is representative of at least 3 independent experiments. Relative luciferase units (RLU).
Supplementary Figure 5. Huh7.5-SEC14L2 cells transfected with the viral constructs were stained for the HCV NS5a protein (green) by immunofluorescence 7 days post transfection to confirm establishment of replication complexes. Mock transfected cells were included as a negative control.
Supplementary Figure 6. (A) Naïve Huh7.5-SEC14L2 cells were infected with Wt and DBN virus with the polymorphisms of interest at a multiplicity of infection of 0.05. Samples were taken at the indicated time points for quantification of HCV RNA by reverse-transcription quantitative polymerase chain reaction. Data presented are representative of 2 independent experiments and analyzed using a Mann-Whitney U test. Graph depicts mean ± SEM. (B, C) An equal inoculum of the Wt and mutant virus was used to infect the cells (multiplicity of infection = 0.03 median tissue culture infectious dose), the relative amounts of the competing viruses were determined by next-generation sequencing at 0, 24, 48, and 72 hours post infection and the percent of Wt (alanine at 150 or lysine at 206) is shown.
**Supplementary Table 1.** Details of clinical samples used in the capture-fusion phenotyping assay

| Patient no. | Therapy          | Outcome | SOF/RBV sensitivity | Age, y | Sex | Cirrhosis        | Previous IFN treatment | Baseline viral load, IU/mL | NS5A RAS, baseline |
|------------|------------------|---------|---------------------|--------|-----|-----------------|------------------------|---------------------------|------------------------|
| 1          | SOF/DAC/RBV      | SVR     | Sensitive           | 59     | M   | Decompensated   | Yes                    | 2,178,912                | —                      |
| 2          | SOF/VEL          | SVR     | Sensitive           | 32     | F   | Compensated     | No                     | 5,992,729                | —                      |
| 3          | Ombitasvir/paritaprevir/ritonavir+SOF | SVR | Sensitive           | 61     | F   | Non-cirrhotic   | Yes                    | 2,301,777                | —                      |
| 4          | SOF/DAC          | SVR     | Sensitive           | 59     | F   | Non-cirrhotic   | No                     | 2,663,854                | —                      |
| 5          | SOF/LDV/RBV      | Relapse | Sensitive           | 47     | M   | Decompensated   | No                     | 2,321,679                | —                      |
| 6          | SOF/DAC/RBV      | Relapse | Sensitive           | 49     | M   | Decompensated   | Yes                    | 1,913,455                | —                      |
| 7          | SOF/LDV/RBV      | Relapse | Sensitive           | 52     | M   | Decompensated   | Yes                    | 808,776                  | —                      |
| 8          | SOF/LDV          | Relapse | Sensitive           | 49     | M   | Decompensated   | No                     | 3,100,000                | —                      |
| 9          | SOF/DAC/RBV      | Relapse | Insensitive         | 48     | M   | Decompensated   | No                     | 1,585,601                | Y93H                   |
| 10         | SOF/LDV/RBV      | Relapse | Insensitive         | 54     | M   | Decompensated   | No                     | 255,934                  | —                      |
| 11         | SOF/DAC/RBV      | Relapse | Insensitive         | 56     | M   | Non-cirrhotic (transplant graft) | Yes | 2,362,045 | — |
| 12         | SOF/DAC/RBV      | Relapse | Insensitive         | 58     | M   | Decompensated   | Yes                    | 902,000                  | —                      |
| 13         | SOF/LDV/RBV      | Relapse | Insensitive         | 43     | M   | Decompensated   | No                     | 5,670,819                | NA                     |
| 14         | SOF/LDV/RBV      | Relapse | Insensitive         | 50     | M   | Decompensated   | Yes                    | 570,000                  | Y93H                   |

**NOTE.** Details of the samples used in the capture fusion assay (Figure 1 and Table 1). Data include treatment, clinical outcome, age, sex, disease status, and baseline viral load. F, female; LDV, ledipasvir; M, male.

**Supplementary Table 2.** 50% Inhibitory Concentration Values of Ribavirin Against Identified Hepatitis C Virus Genotype 3a Polymorphisms Compared With the Wild-Type S52 Replicon

| S52 replicon | RBV IC$_{50}$ (85% CI), $\mu$M | Fold-change in RBV IC$_{50}$ | Luciferase levels, % of Wt, mean ± SEM |
|--------------|---------------------------------|-----------------------------|--------------------------------------|
| Wt           | 0.70 (0.47–1.05)                | 1.00                        | 100.00 ± 10.33                       |
| K100R        | 23.61 (9.96–55.95)              | 32.85                       | 72.45 ± 13.18                       |
| A150V        | 28.03 (17.14–45.83)             | 40.04                       | 98.17 ± 11.59                       |
| G188D        | 15.19 (4.94–46.67)              | 21.70                       | 74.02 ± 17.11                       |
| K206E        | 7.40 (4.66–11.75)               | 10.57                       | 59.35 ± 21.06                       |
| T213N        | 6.12 (3.58–10.54)               | 8.74                        | 108.20 ± 18.19                      |
| N244I        | 1.49 (0.78–2.86)                | 2.13                        | 55.95 ± 13.01                       |
| K100R+G188D  | 7.27 (5.15–10.25)               | 10.35                       | 40.96 ± 14.51                       |
| A150V+K206E  | 48.69 (20.81–113.9)             | 69.55                       | 120.4 ± 17.75                       |

**NOTE.** The calculated IC$_{50}$ values with 95% CIs and the fold-change compared to the Wt replicon from Supplementary Figures 3 and 4 were replicons were treated with RBV, are summarized. Relative luciferase levels compared to the Wt replicon construct for each polymorphism were also included.